Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 7.


Stockdale, Alexander J ORCID: 0000-0002-5828-3328, Saunders, Matthew J, Boyd, Mark A, Bonnett, Laura J ORCID: 0000-0002-6981-9212, Johnston, Victoria, Wandeler, Gilles, Schoffelen, Annelot F, Ciaffi, Laura, Stafford, Kristen, Collier, Ann C
et al (show 2 more authors) (2018) Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor–Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 66 (12). pp. 1846-1857.


Arenas-Pinto, Alejandro, Stohr, Wolfgang, Clarke, Amanda, Williams, Ian, Beeching, Nicholas J ORCID: 0000-0002-7019-8791, Minton, Jane, Lee, Vincent and Paton, Nicholas I
(2017) Evaluation of cerebrospinal fluid virological escape in patients on long-term protease inhibitor monotherapy. ANTIVIRAL THERAPY, 22 (6). pp. 535-538.


Stohr, Wolfgang, Dunn, David T, Arenas-Pinto, Alejandro, Orkin, Chloe, Clarke, Amanda, Williams, Ian, Johnson, Margaret, Beeching, Nicholas J ORCID: 0000-0002-7019-8791, Wilkins, Edmund, Sanders, Karen
et al (show 1 more authors) (2016) Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy. AIDS, 30 (17). pp. 2617-2624.


Kityo, Cissy, Thompson, Jennifer, Nankya, Immaculate, Hoppe, Anne, Ndashimye, Emmanuel, Warambwa, Colin, Mambule, Ivan, van Oosterhout, Joep J, Wools-Kaloustian, Kara, Bertagnolio, Silvia
et al (show 4 more authors) (2017) HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 75 (2). E45-E54.


Hakim, James G, Thompson, Jennifer, Kityo, Cissy, Hoppe, Anne, Kambugu, Andrew, van Oosterhout, Joep J, Lugemwa, Abbas, Siika, Abraham, Mwebaze, Raymond, Mweemba, Aggrey
et al (show 7 more authors) (2017) Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. The Lancet. Infectious diseases, 18 (1). pp. 47-57.


Shi, Yuan, Thompson, Jennifer, Walker, A Sarah, Paton, Nicholas I, Cheung, Yin Bun, Agweng, E, Awio, P, Bakeinyaga, G, Isabirye, C, Kabuga, U
et al (show 272 more authors) (2019) Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3L) utility index. HEALTH AND QUALITY OF LIFE OUTCOMES, 17 (1). 83-.


Paton, Nicholas I, Kityo, Cissy, Thompson, Jennifer, Nankya, Immaculate, Bagenda, Leonard, Hoppe, Anne, Hakim, James, Kambugu, Andrew, van Oosterhout, Joep J, Kiconco, Mary
et al (show 5 more authors) (2017) Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. The lancet. HIV, 4 (8). e341-e348.

This list was generated on Sat Mar 2 09:11:16 2024 GMT.